LLY · 8-K · 20260805PR000077

Pricing Pressure - GLP-1

ELI LILLY & Co · 2026-08-05 · Importance 32 · Surprise 40

Lilly reported a 13% decrease in worldwide realized prices in Q2 2026, partially offsetting a 60% increase in volume. U.S. realized prices declined 3%, or approximately 9% excluding rebate and discount estimate adjustments, primarily due to Zepbound and Mounjaro. Outside the U.S., realized prices declined 36%, driven primarily by Mounjaro's addition to China's National Reimbursement Drug List (NRDL). Zepbound pricing also reflected previously announced reductions in cash-pay prices.

Key facts

• Excluding adjustments for rebates and discounts, U.S. price would have declined by approximately 9% in Q2 2026. source